Back to School: How biopharma can reboot drug development. Access exclusive analysis here
The double-blind, U.K. Phase II RN1004-0082 trial in 195 patients showed that 300 and 600 mM Juvidex missed the primary endpoint of a
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury